Although we did not perform immunofluorescent co-expression studies, we found statistical correlation of HELLS and EZH2 expression within the same patients and individual tissue microarray cores, suggesting a link of both DNA- and histone-methylation pathways within prostate cancer patients as has previously been shown in in vitro models [26]. Here, EZH2 is linked to prostate carcinoma.